Literature DB >> 11759111

Secretory leukocyte protease inhibitor in punch biopsies from human colonic mucosa.

M Nyström1, U P Westin, C Linder, K Ohlsson.   

Abstract

Secretory leukocyte protease inhibitor (SLPI) is a well-known protease inhibitor. Its function is thought to be protease/protease-inhibitor balance. Free proteolytic activity, mainly pancreatic elastase, anionic trypsin and granulocytic elastase, has been demonstrated in faecal extracts from patients with ulcerative colitis. We wanted to verify that SLPI is actually secreted from normal human colonic mucosa. Also, we wanted to ascertain whether studies of SLPI secretion based on punch biopsies were dependent on biopsy area or on biopsy circumference. Normal colonic mucosa was sampled during surgery for colonic cancer. A total of 36 samples from four patients were used. Mucosa preparation was carried out using a punch biopsy technique, and samples of 3, 4 and 6 mm diameter were used. All media contained SLPI at varying concentrations. When expressed in terms of the sample area, the secretion per millimetre-squared seemed to decrease with increasing area. When calculated as secretion per circumference, secretion seemed to be constant. In conclusion, SLPI was secreted from normal human colonic mucosa. The SLPI secretion seemed dependent on the circumference of the biopsy rather than on the area of the biopsy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11759111      PMCID: PMC1781715          DOI: 10.1080/09629350120093740

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  18 in total

1.  The interactions between a low molecular weight protease inhibitor of bronchial mucus and chymotrypsin-like cationic proteins of granulocytes.

Authors:  H Tegner; K Ohlsson; I Olsson
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1977-04

2.  [Isolation and characterisation of a protease inhibitor from human bronchial secretion].

Authors:  K Hochstrasser; R Reichert; S Schwarz; E Werle
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1972-02

3.  Localisation of a low-molecular-weight bronchial protease inhibitor in the peripheral human lung.

Authors:  H W Mooren; J A Kramps; C Franken; C J Meijer; J A Dijkman
Journal:  Thorax       Date:  1983-03       Impact factor: 9.139

4.  Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription.

Authors:  T B McNeely; D C Shugars; M Rosendahl; C Tucker; S P Eisenberg; S M Wahl
Journal:  Blood       Date:  1997-08-01       Impact factor: 22.113

5.  Influence of plasma proteinase inhibitors and the secretory leucocyte proteinase inhibitor on pancreatic elastase-induced degradation of some plasma proteins.

Authors:  H O Håkansson; K Ohlsson
Journal:  Gastroenterol Jpn       Date:  1992-10

6.  Pancreatic and granulocytic endoproteases in faecal extracts from patients with active ulcerative colitis.

Authors:  M Bohe
Journal:  Scand J Gastroenterol       Date:  1987-01       Impact factor: 2.423

7.  Determination of immunoreactive trypsin, pancreatic elastase and chymotrypsin in extracts of human feces and ileostomy drainage.

Authors:  M Bohe; A Borgström; S Genell; K Ohlsson
Journal:  Digestion       Date:  1983       Impact factor: 3.216

8.  Quantification of granulocyte elastase inhibitors in human mixed saliva and in pure parotid secretion.

Authors:  M Ohlsson; M Rosengren; H Tegner; K Ohlsson
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1983-09

9.  Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase.

Authors:  R C Thompson; K Ohlsson
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

10.  Inhibition of elastase from granulocytes by the low molecular weight bronchial protease inhibitor.

Authors:  K Ohlsson; H Tegner
Journal:  Scand J Clin Lab Invest       Date:  1976-09       Impact factor: 1.713

View more
  3 in total

1.  Novel anti-inflammatory role of SLPI in adipose tissue and its regulation by high fat diet.

Authors:  Venkata J Adapala; Kimberly K Buhman; Kolapo M Ajuwon
Journal:  J Inflamm (Lond)       Date:  2011-02-28       Impact factor: 4.981

2.  Intestinal protease-activated receptor-2 and fecal serine protease activity are increased in canine inflammatory bowel disease and may contribute to intestinal cytokine expression.

Authors:  Shingo Maeda; Koichi Ohno; Kazuyuki Uchida; Hirotaka Igarashi; Yuko Goto-Koshino; Yasuhito Fujino; Hajime Tsujimoto
Journal:  J Vet Med Sci       Date:  2014-05-15       Impact factor: 1.267

3.  Inhibition of gelatinase B/MMP-9 does not attenuate colitis in murine models of inflammatory bowel disease.

Authors:  Magali de Bruyn; Christine Breynaert; Ingrid Arijs; Gert De Hertogh; Karel Geboes; Greet Thijs; Gianluca Matteoli; Jialiang Hu; Jo Van Damme; Bernd Arnold; Marc Ferrante; Séverine Vermeire; Gert Van Assche; Ghislain Opdenakker
Journal:  Nat Commun       Date:  2017-05-31       Impact factor: 14.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.